| Literature DB >> 28672794 |
Damiana Pieragostino1,2, Luca Agnifili3, Ilaria Cicalini4,5, Roberta Calienno6, Mirco Zucchelli7,8, Leonardo Mastropasqua9, Paolo Sacchetta10,11, Piero Del Boccio12,13, Claudia Rossi14,15.
Abstract
Dry eye disease (DED) is a multifactorial disorder of the ocular surface unit resulting in eye discomfort, visual disturbance, and ocular surface damage; the risk of DED increases with age in both sexes, while its incidence is higher among females caused by an overall hormonal imbalance. The role of androgens has recently investigated and these hormones were considered to have a protective function on the ocular surface. In order to correlate DED to tear steroid levels, a robust, specific, and selective method for the simultaneous quantification of cortisol (CORT), corticosterone (CCONE), 11-deoxycortisol (11-DECOL), 4-androstene-3,17-dione (ADIONE), testosterone (TESTO), 17α-hydroxyprogesterone (17-OHP), and progesterone (PROG) was developed and applied for the analysis of tear samples. The method involves a simple extraction procedure of steroids from tears collected on Schirmer strips, followed by a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) analysis. In total, tear samples from 14 DED female patients and 13 healthy female controls were analysed and, CORT, ADIONE, and 17-OHP response levels resulted significantly decreased in dry eye patients respect to controls. The receiver operating characteristic (ROC) curve obtained by the combination of these three steroids (AUC = 0.964) demonstrated the good diagnostic power of the differential tear steroids in identifying DED. In conclusion, the present method made it possible, for the first time, to study steroid profiling directly in tear fluid.Entities:
Keywords: LC-MS/MS; biomarkers; dry eye disease; mass spectrometry; steroids; tears
Mesh:
Substances:
Year: 2017 PMID: 28672794 PMCID: PMC5535842 DOI: 10.3390/ijms18071349
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The chromatogram obtained at the upper concentration for each analyte through the proposed high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method shows a good resolution among the investigated steroids. Additionally, the two isomers corticosterone (CCONE) and 11-deoxycortisol (11-DECOL) are chromatographically resolved.
Concentration ranges, calculated calibration functions, and correlation coefficients (r). a b1 and b0 are mean values (n = 5). b Weight = 1/x. Cortisol (CORT); 4-androstene-3,17-dione (ADIONE); testosterone (TESTO); 17α-hydroxyprogesterone (17-OHP); and progesterone (PROG).
| Analyte | Concentration Range (ng/mL) | Calibration Function | |
|---|---|---|---|
| CORT | 0.3–20.08 | 0.996 | |
| 11-DECOL | 0.05–1.00 | 0.994 | |
| ADIONE | 0.05–2.91 | 0.994 | |
| TESTO | 0.02–1.00 | 0.993 | |
| 17-OHP | 0.05–4.20 | 0.993 | |
| PROG | 0.05–4.20 | 0.994 |
Intra- and inter-day precision and accuracy. Intra- and inter-assay precision, expressed as coefficient of variation (%CV), and recovery data evaluated at each Quality Control (QC) level. Standard deviation (SD).
| Intra-Assay | Inter-Assay | Recovery % | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Compound | QC Level | Mean Response | SD | %CV | Mean Response | SD | %CV | Mean | SD |
| CORT | QC1 | 0.13 | 0.02 | 13.47 | 0.14 | 0.01 | 8.43 | 50.12 | 13.18 |
| QC2 | 0.52 | 0.01 | 2.35 | 0.52 | 0.03 | 5.12 | 33.12 | 0.73 | |
| QC3 | 2.88 | 0.15 | 5.09 | 2.57 | 0.13 | 5.14 | 44.29 | 1.98 | |
| 11-DECOL | QC1 | 0.27 | 0.02 | 7.97 | 0.15 | 0.02 | 12.41 | 46.99 | 6.64 |
| QC2 | 0.67 | 0.01 | 1.63 | 0.72 | 0.06 | 7.83 | 67.45 | 6.67 | |
| QC3 | 2.19 | 0.11 | 4.98 | 2.26 | 0.21 | 9.48 | 58.18 | 2.83 | |
| ADIONE | QC1 | 0.83 | 0.04 | 4.99 | 0.99 | 0.03 | 3.15 | 23.26 | 7.16 |
| QC2 | 2.14 | 0.10 | 4.77 | 2.30 | 0.15 | 6.72 | 22.01 | 2.26 | |
| QC3 | 11.99 | 0.13 | 1.12 | 11.85 | 0.32 | 2.73 | 24.53 | 2.23 | |
| TESTO | QC1 | 0.67 | 0.09 | 13.82 | 0.56 | 0.05 | 8.77 | 19.50 | 2.92 |
| QC2 | 2.14 | 0.31 | 14.67 | 1.92 | 0.09 | 4.51 | 37.46 | 0.48 | |
| QC3 | 6.39 | 0.73 | 11.49 | 5.29 | 0.74 | 13.94 | 44.85 | 5.91 | |
| 17-OHP | QC1 | 0.21 | 0.03 | 15.24 | 0.35 | 0.04 | 10.84 | 22.78 | 9.92 |
| QC2 | 0.78 | 0.07 | 8.86 | 1.04 | 0.06 | 5.99 | 30.61 | 6.49 | |
| QC3 | 6.25 | 0.17 | 2.77 | 6.76 | 0.62 | 9.15 | 50.64 | 2.60 | |
| PROG | QC1 | 0.83 | 0.03 | 3.20 | 1.01 | 0.07 | 6.90 | 39.56 | 4.31 |
| QC2 | 2.26 | 0.21 | 9.54 | 2.95 | 0.19 | 6.70 | 30.60 | 1.92 | |
| QC3 | 13.92 | 0.10 | 0.72 | 14.77 | 1.22 | 8.30 | 40.43 | 7.50 | |
Figure 2(A) Tear steroid profiling of dry eye (n = 14) and of healthy control patients (n = 13). Data are mean values and bars represent the corresponding standard deviations (SD); (B–D) Tear sample distribution for the significantly different steroids: CORT, ADIONE and 17-OHP response levels, respectively. ** indicates p < 0.01 and *** indicates p < 0.001.
Figure 3(A) Receiver operating characteristic (ROC) curve performed on the three significantly different steroids calculated (CORT, ADIONE, and 17-OHP) resulting in an AUC = 0.964; (B) The 100 cross-validation is shown, underlying good predictivity of the proposed model (p < 0.01) in differentiating dry eye patients from healthy people; (C) Samples are grouped in class 0 and 1 for controls and dry eye patients, respectively.
Concentration levels (ng/mL) for calibrators and QC materials of each steroid monitored in the LC-MS/MS method of analysis are summarized.
| Analyte | Calibration Levels (ng/mL) | QC Levels (ng/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| L1 | L2 | L3 | L4 | L5 | L6 | L7 | QC1 | QC2 | QC3 | |
| CORT | 0.30 | 0.50 | 1.00 | 1.51 | 3.61 | 8.66 | 20.80 | 0.50 | 1.51 | 8.66 |
| CCONE | 0.05 | 0.10 | 0.20 | 0.29 | 0.70 | 1.68 | 4.03 | 0.10 | 0.29 | 1.68 |
| 11-DECOL | 0.05 | 0.07 | 0.10 | 0.20 | 0.40 | 0.70 | 1.00 | 0.07 | 0.20 | 0.70 |
| ADIONE | 0.05 | 0.08 | 0.10 | 0.20 | 0.49 | 1.17 | 2.91 | 0.08 | 0.20 | 1.17 |
| TESTO | 0.02 | 0.05 | 0.08 | 0.15 | 0.30 | 0.60 | 1.00 | 0.05 | 0.15 | 0.60 |
| 17-OHP | 0.05 | 0.08 | 0.12 | 0.29 | 0.70 | 1.69 | 4.20 | 0.08 | 0.29 | 1.69 |
| PROG | 0.05 | 0.08 | 0.12 | 0.29 | 0.70 | 1.69 | 4.20 | 0.08 | 0.29 | 1.69 |
MS/MS operating conditions. Multiple reaction monitoring (MRM) functions and settings for detection of steroids are shown. Italics denotes qualifier ion.
| MRM Function | Time Window (min) | Analyte | Transitions ( | Cone Volts | Coll Energy (eV) |
|---|---|---|---|---|---|
| 1 | 5.0–8.5 | CORT | 363.2 > 120.8 | 100 | 20 |
| 2H3-CORT | 366.2 > 120.8 | 100 | 20 | ||
| 2 | 8.0–10.5 | CCONE | 347.3 > 120.8 | 100 | 18 |
| 2H8-CCONE | 355.3 > 124.8 | 100 | 18 | ||
| 3 | 8.0–10.8 | 11-DECOL | 347.3 > 108.8 | 100 | 22 |
| 2H5-11-DECOL | 352.3 > 112.8 | 100 | 22 | ||
| 4 | 9.7–12.0 | ADIONE | 287.2 > 96.9 | 100 | 18 |
| 2H5-ADIONE | 292.2 > 99.9 | 100 | 18 | ||
| 5 | 10.5–13.0 | TESTO | 289.2 > 96.8 | 100 | 19 |
| 2H5-TESTO | 294.2 > 99.8 | 100 | 19 | ||
| 6 | 11.2–13.5 | 17-OHP | 331.2 > 96.8 | 100 | 21 |
| 2H8-OHP | 339.2 > 99.8 | 100 | 21 | ||
| 7 | 13.5–16.0 | PROG | 315.2 > 96.9 | 100 | 18 |
| 2H9-PROG | 324.2 > 99.9 | 100 | 18 |